Laminite endocrinopática em equinos com síndrome metabólica: características clínicas, tratamento e evolução em três pacientes ˗ relato de caso / [Endocrinopathic laminitis in horses with metabolic syndrome: clinical characteristics, treatment and evolution in three patients ˗ case report]

Laminite endocrinopática designa os casos de laminite cuja etiologia está associada a uma endocrinopatia. Cavalos com síndrome metabólica equina (SME) apresentam adiposidade regional e obesidade. Existe uma correlação positiva entre obesidade e resistência à insulina. Este relato descreve três casos de laminite endocrinopática em cavalos com SME. Os pacientes apresentaram escore de condição corporal (ECC) variando de 8 a 9 (escala de 1 a 9), sensibilidade ao teste de pinçamento do casco e claudicação de grau 3 ou 4 (escala de 1 a 4). Não havia histórico de cólica recente, trauma ou excesso de exercício. O tratamento incluiu medicação anti-inflamatória não esteroidal, repouso na baia, restrição energética para perda de peso, revestimento e bandagem dos membros, conforme a necessidade de cada paciente. A restrição alimentar ajudou no tratamento da SME e reduziu o ECC. Tratamento medicamentoso, casqueamento e bandagem diminuíram o grau de claudicação. Conclui-se que o tratamento anti-inflamatório não esteroidal, a restrição energética, o repouso em baia, o casqueamento e a bandagem do casco são eficazes no tratamento da laminite endocrinopática em cavalos com síndrome metabólica equina.(AU)

Endocrinopathic laminitis refers to cases of laminitis whose etiology is associated with an endocrinopathy. Horses with Equine Metabolic Syndrome (EMS) have regional adiposity and obesity. There is a positive correlation between obesity and insulin resistance. This report describes three cases of endocrinopathic laminitis in horses with EMS. Patients had body condition score (BCS) ranging from 8 to 9 (scale from 1 to 9), sensitivity to the hoof clamping test and claudication grade 3 or 4 (scale from 1 to 4). There was no history of recent colic, trauma or over exercise. Treatment included non-steroidal anti-inflammatory medication, stall rest, energy restriction for weight loss, hoofing and hoof bandage as needed by each patient. Dietary restriction helped in the treatment of EMS and reduced BCS. Drug treatment, hoofing and hoof bandage decreased the degree of lameness. It is concluded that non-steroidal anti-inflammatory treatment, energy restriction, stall rest, hoofing and hoof bandage are effective in the treatment of endocrinopathic laminitis in horses with equine metabolic syndrome.(AU)

In vitro anthelmintic activity of Siparuna guianensis extract and essential oil against Strongyloides venezuelensis.

New therapeutic approaches are necessary to control strongyloidiasis due to the side effects of, and resistance to, currently available drugs thiabendazole, albendazole, and ivermectin. This study examined the anthelmintic properties of extracts and isolated compounds from Siparuna guianensis against Strongyloides venezuelensis eggs and larvae, using the egg hatching test (EHT) and larval motility test (LMT). Albendazole (0.025 mg/ml) and ivermectin (0.316 mg/ml) were used as the positive controls for the EHT and LMT assays, respectively. Strongyloides venezuelensis eggs or larvae (±50 specimens) were treated with ethanol extract (0.05-1.0 mg/ml), ethyl acetate and aqueous fractions (0.05-0.8 mg/ml), essential oil (0.2-1.0 mg/ml) and α-bisabolol (0.2-1.0 mg/ml) from S. guianensis, and analysed by optical microscopy after 48 h (EHT), or after 24, 48 and 72 h (LMT). All the tested compounds exhibited ovicidal activity equivalent to the positive control and changed the morphology of the eggs. The S. guianensis ethanol extract and aqueous fraction were as effective as the positive control. Phytochemical analysis of the ethanol extract and fractions revealed the presence of phenolic compounds, tannins and flavonoids. Therefore, S. guianensis is effective against S. venezuelensis eggs and larvae in vitro, and can be considered as a potential alternative treatment for strongyloidiasis.